These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26873482)

  • 41. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Automatic detection of adverse events to predict drug label changes using text and data mining techniques.
    Gurulingappa H; Toldo L; Rajput AM; Kors JA; Taweel A; Tayrouz Y
    Pharmacoepidemiol Drug Saf; 2013 Nov; 22(11):1189-94. PubMed ID: 23935003
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.
    Lai EC; Pratt N; Hsieh CY; Lin SJ; Pottegård A; Roughead EE; Kao Yang YH; Hallas J
    Eur J Epidemiol; 2017 Jul; 32(7):567-582. PubMed ID: 28698923
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification.
    Osokogu OU; Dodd C; Pacurariu A; Kaguelidou F; Weibel D; Sturkenboom MC
    Drug Saf; 2016 Sep; 39(9):873-81. PubMed ID: 27255487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports.
    Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J
    Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing performance of sequential analysis methods for active drug safety surveillance using observational data.
    Zhou X; Bao W; Gaffney M; Shen R; Young S; Bate A
    J Biopharm Stat; 2018; 28(4):668-681. PubMed ID: 29157113
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases.
    Cliff-Eribo KO; Sammons H; Choonara I
    Expert Opin Drug Saf; 2016 Oct; 15(10):1321-8. PubMed ID: 27501085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secret safety warnings on medicines: A case study of information access requests.
    Torka M; Mintzes B; Bhasale A; Fabbri A; Perry L; Lexchin J
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):551-555. PubMed ID: 30840349
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Comparative relevance of declaration of side effects by patients and health professionals].
    Lagneau A; Vigier C; Marianna A; Serfaty R; Rocher F; Spreux A; Drici MD
    Therapie; 2017 Dec; 72(6):625-633. PubMed ID: 28780021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential utility of data-mining algorithms for early detection of potentially fatal/disabling adverse drug reactions: a retrospective evaluation.
    Hauben M; Reich L
    J Clin Pharmacol; 2005 Apr; 45(4):378-84. PubMed ID: 15778418
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug safety issues of nimesulide in China--nimesulide-induced liver injury.
    Wang Y; Zeng Y; Xu F
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):778-9. PubMed ID: 21714032
    [No Abstract]   [Full Text] [Related]  

  • 56. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project.
    Abbing-Karahagopian V; Kurz X; de Vries F; van Staa TP; Alvarez Y; Hesse U; Hasford J; Dijk Lv; de Abajo FJ; Weil JG; Grimaldi-Bensouda L; Egberts AC; Reynolds RF; Klungel OH
    Curr Clin Pharmacol; 2014 May; 9(2):130-8. PubMed ID: 24218995
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
    Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 60. From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.
    Trifirò G; Sultana J; Bate A
    Drug Saf; 2018 Feb; 41(2):143-149. PubMed ID: 28840504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.